Methylene Blue for ALS
Also known as: Methylthioninium chloride
Methylene blue's ability to bypass mitochondrial Complex III dysfunction and reduce oxidative stress is relevant to ALS motor neuron degeneration.
Mechanism of Action
In ALS, mitochondrial dysfunction is a key pathological feature. Methylene blue's alternative electron transport pathway (Complex I → Complex IV bypass) can maintain ATP production in neurons with impaired Complex III function. It also reduces ROS generation and inhibits protein aggregation relevant to TDP-43 pathology.
General mechanism: Mitochondrial electron carrier (Complex I → IV bypass). Tau aggregation inhibitor. Alternative redox cycling agent.
Current Evidence
Preclinical studies show neuroprotective effects in ALS models (SOD1 mice). Limited human data. The mitochondrial bypass mechanism is well-characterized but clinical translation for ALS is early stage.
Clinical Status: Preclinical for ALS. FDA-approved for methemoglobinemia. Repurposing investigation ongoing.
Safety Profile
Generally well-tolerated at low doses. Serotonin syndrome risk with SSRIs/MAOIs. Blue discoloration of urine. G6PD deficiency contraindication.
Key Research Questions
- Can methylene blue protect motor neurons from TDP-43-mediated mitochondrial damage?
- What is the optimal dosing for CNS mitochondrial support?
Frequently Asked Questions
Is methylene blue safe for brain health?
Methylene blue at low doses (0.5-2mg/kg) acts as a mitochondrial electron carrier, enhancing Complex IV function and ATP production. It's FDA-approved for methemoglobinemia. Neurological research doses are much lower than treatment doses. Contraindicated with SSRIs (serotonin syndrome risk).
Methylene blue for Alzheimer's research
Methylene blue inhibits tau aggregation, enhances mitochondrial function, and reduces oxidative stress. The TauRx Phase III trials (LMTM/hydromethylthionine) showed benefit as monotherapy but not as add-on to standard AD drugs. Research continues into optimal dosing and patient selection.